#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Erythema multiforme Hypochondroplasia Leiomyosarcoma Osteosarcoma metastatic Astrocytoma Multiple system atrophy Gastroenteropancreatic neuroendocrine tumour disease Von Willebrand's disease Arteriosclerosis Adult T-cell lymphoma/leukaemia refractory Postprandial hypoglycaemia Blastic plasmacytoid dendritic cell neoplasia Duchenne muscular dystrophy Richter's syndrome Primary amyloidosis More trials…

    Learn about Rare Diseases

    Familial haemophagocytic lymphohistiocytosis – Trials in Disease Breast angiosarcoma – Trials in Disease Lymphangioma – Diagnostics Ewing’s sarcoma recurrent – Basic Information Piriformis syndrome – Basic Information Mantle cell lymphoma refractory – Diagnostics Hypereosinophilic syndrome – Diagnostics Lennox-Gastaut syndrome – Treatment Propionic acidaemia – Treatment Fragile X syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Citalopram Hydrobromide Calcium Carbonate Betula Pollen Extract Izorlisib Mesilate SPY002 PETHIDINE HYDROCHLORIDE Ilofotase Alfa ALKYLATING AGENTS AGANIRSEN Rbl027.2 Warfarin Sodium Oxytocin Synthetic Doxribtimine Surzebiclimab Nilotinib Ranitidine Hydrochloride L-LEUCINE Cdr132L Xenon Casimersen More therapies…

    Learn about Your Condition

    Mucopolysaccharidosis Major depression Thrombolysis Arginase deficiency Rheumatic disorder Cardiovascular disorder Diabetic gastroparesis Thromboangiitis obliterans Leber's congenital amaurosis Breast cancer recurrent Gallbladder cancer Kaposi's sarcoma H1N1 influenza Primary amyloidosis Post-traumatic stress disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Primary progressive multiple sclerosis

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Secondary progressive multiple sclerosis
    • Primary progressive multiple sclerosis
    Investigated Drugs:
    • Fludarabine Phosphate
    • Rapcabtagene Autoleucel
    • Cyclophosphamide
    France Germany Italy Spain

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Diseases:
    • Primary progressive multiple sclerosis
    Investigated Drugs:
    • Tolebrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Study Comparing Rituximab and Ocrelizumab for Patients with Active Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Secondary progressive multiple sclerosis
    • Primary progressive multiple sclerosis
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Rituximab
    Denmark

  • Study on the Safety and Effectiveness of Melatonin and Ocrelizumab for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Primary progressive multiple sclerosis
    Investigated Drugs:
    • Benzyl Alcohol
    • Melatonin
    • Propylene Glycol
    Spain

  • Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary progressive multiple sclerosis
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Methylprednisolone Sodium Succinate
    • Ocrelizumab
    Belgium Bulgaria Croatia France Italy Poland +3
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!